TAE226 inhibits human neuroblastoma cell survival.
OBJECTIVE
Neuroblastoma is one of the most devastating pediatric solid tumors and is unresponsive to many interventions. TAE226 is a novel small molecule FAK inhibitor. We investigated the effects of TAE226 on neuroblastoma cells in vitro.


METHODS
Human neuroblastoma cell lines were treated with varying concentrations of TAE226. Following treatment, cell viability, cell cycle, and apoptosis were evaluated.


RESULTS
Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis.


CONCLUSIONS
Targeting FAK provides potential therapeutic options for the treatment of neuroblastoma and deserves further investigation.
Beierle
Elizabeth A
EA
Department of Surgery, University of Florida, Gainesville, Florida 32610-0286, USA. beierea@surgery.ufl.edu
Trujillo
Angelica
A
Nagaram
Abhilasha
A
Golubovskaya
Vita M
VM
Cance
William G
WG
Kurenova
Elena V
EV
D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D051417:Focal Adhesion Kinase 1 / Q000037:antagonists & inhibitors*; D006801:Humans; D009025:Morpholines / Q000494:pharmacology*; D009447:Neuroblastoma / Q000188:drug therapy* / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D014407:Tumor Cells, Cultured / Q000187:drug effects
D009025:Morpholines; C524632:TAE226; D051417:Focal Adhesion Kinase 1